TEL AVIV, Israel & FREMONT, Calif.--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) and DiscoveRx Corporation announced today that they have entered into a collaborative partnership for the purpose of commercializing novel Compugen designed peptides to be matched with specific G protein-coupled receptor (“GPCR”) targets utilizing DiscoveRx GPCR related technologies. The new agreement follows a successful pilot program between the two companies.
